Dodge & Cox Neurocrine Biosciences Inc Call Options Transaction History
Dodge & Cox
- $166 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
656Shares Held
101MCall Options Held
282KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.83 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.26 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.47MShares$576 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$398 Million0.04% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$344 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...